文献速递临床试验与 GCP流行病学与生物统计

极早产儿脑氧饱和度监测与常规护理对比:SafeBoosC-III随机临床试验2年随访研究方案

Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the 2-year follow-up of the SafeBoosC-III randomised clinical trial.
PubMed 文献 · Trials · 2023-10-07

SafeBoosC-III试验中,出生后72小时内以脑氧饱和度监测指导治疗与常规护理相比,未降低极早产儿在矫正胎龄36周时的死亡或严重脑损伤发生率。本随访研究旨在评估试验参与者在矫正年龄2岁时的死亡率、神经发育障碍或任何伤害,计划从1276名存活婴儿的常规随访项目中收集数据。

要点

  • SafeBoosC-III试验中脑氧饱和度监测指导治疗未降低36周胎龄时死亡或严重脑损伤发生率。
  • 2年随访研究纳入1276名在36周胎龄时存活的婴儿,评估死亡或中重度神经发育障碍复合结局及Bayley-III/IV认知评分。
  • 采用三级数据质量优先模型以减少失访,数据来源包括常规随访、其他医疗记录和父母问卷。

核心结论

  • SafeBoosC-III试验中脑氧饱和度监测指导治疗与常规护理相比未降低极早产儿36周胎龄时死亡或严重脑损伤发生率,本随访研究将评估2岁矫正年龄时的死亡、神经发育障碍或任何伤害。

研究设计与样本

  • SafeBoosC-III随机临床试验的2年随访研究方案,纳入1601名随机化婴儿中36周胎龄时存活的1276名,计划收集矫正年龄18至30个月常规随访数据,无常规随访时收集至少12个月时的非正式评估。
  • 由对分组分配设盲的当地共同研究者基于记录分类结局,并补充父母问卷包括Parent Report of Children's Abilities-Revised。
  • 设置两个共同主要结局:死亡或中重度神经发育障碍的复合结局,以及Bayley-III/IV平均认知评分;采用基于数据质量的三级优先模型。

主要发现

  • SafeBoosC-III试验中,出生后72小时内脑氧饱和度监测指导治疗与常规护理相比,未降低36周胎龄时死亡或严重脑损伤发生率(原文未报告具体数值)。
  • 本随访研究计划评估1276名存活婴儿在2岁矫正年龄时的死亡、神经发育障碍或任何伤害。

关键数值与推荐

  • 纳入标准:入住参与随访研究的新生儿重症监护病房,并按当地法规要求获得父母知情同意。
  • 数据收集年龄范围:常规随访为矫正年龄18至30个月;无常规随访时收集至少12个月时的非正式评估。
  • 两个共同主要结局:死亡或中重度神经发育障碍的复合结局,以及Bayley-III/IV平均认知评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出一个重要挑战是缺乏资金支付试验特异性评估的当地费用。
  • 原文指出由于资金有限,需要采用务实的方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the SafeBoosC-III trial, treatment guided by cerebral oximetry monitoring for the first 72 hours after birth did not reduce the incidence of death or severe brain injury in extremely preterm infants at 36 weeks' postmenstrual age, as compared with usual care. Despite an association between severe brain injury diagnosed in the neonatal period and later neurodevelopmental disability, this relationship is not always strong. The objective of the SafeBoosC-III follow-up study is to assess mortality, neurodevelopmental disability, or any harm in trial participants at 2 years of corrected age. One important challenge is the lack of funding for local costs for a trial-specific assessment. METHODS: Of the 1601 infants randomised in the SafeBoosC-III trial, 1276 infants were alive at 36 weeks' postmenstrual age and will potentially be available for the 2-year follow-up. Inclusion criteria will be enrollment in a neonatal intensive care unit taking part in the follow-up study and parental consent if required by local regulations. We aim to collect data from routine follow-up programmes between the ages of 18 and 30 months of corrected age. If no routine follow-up has been conducted, we will collect informal assessments from other health care records from the age of at least 12 months. A local co-investigator blinded to group allocation will classify outcomes based on these records. We will supplement this with parental questionnaires including the Parent Report of Children's Abilities-Revised. There will be two co-primary outcomes: the composite of death or moderate or severe neurodevelopmental disability and mean Bayley-III/IV cognitive score. We will use a 3-tier model for prioritisation, based on the quality of data. This approach has been chosen to minimise loss to follow-up assuming that little data is better than no data at all. DISCUSSION: Follow-up at the age of 2 years is important for intervention trials in the newborn period as only time can show real benefits and harms later in childhood. To decrease the risk of generalisation and data-driven biased conclusions, we present a detailed description of the methodology for the SafeBoosC-III follow-up study. As funding is limited, a pragmatic approach is necessary. TRIAL REGISTRATION: ClinicalTrials.gov NCT05134116 . Registered on 24 November 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rasmussen MI, Hansen ML, Pellicer A, et al. Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the 2-year follow-up of the SafeBoosC-III randomised clinical trial. Trials. 2023. PMID: 37805539. doi:10.1186/s13063-023-07653-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。